Organization
Clinical Research Centre Ltd, Tartu, Estonia
3 abstracts
Abstract
APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (52-WEEK) IMPROVEMENTS IN BASDAI IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM 3 PHASE III, RANDOMIZED, CONTROLLED TRIALS Org: Swedish Medical Center and University of Washington School of Medicine, Seattle, United States, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, Clinical Research Centre Ltd, Tartu, Estonia, UZ Gent, Gent, Belgium, Schön Klinik Hamburg Eilbek, Hamburg, Germany,
Abstract
APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (156-WEEK) IMPROVEMENTS IN BASDAI IN PSORIATIC ARTHRITIS PATIENTS: POOLED RESULTS FROM 3 PHASE III, RANDOMIZED, CONTROLLED TRIALS Org: Swedish Medical Center and University of Washington School of Medicine, Seattle, United States, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals and University of Leeds, Leeds, United Kingdom, Clinical Research Centre Ltd, Tartu, Estonia, UZ Gent, Gent, Belgium, Schön Klinik Hamburg Eilbek, Hamburg, Germany,
Abstract
APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (104-WEEK) IMPROVEMENT IN FATIGUE IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM 3 PHASE III, RANDOMIZED, CONTROLLED TRIALS Org: Toronto Western Research Institute, Toronto, Canada, University Hospital Southampton, Southampton, United Kingdom, Clinical Research Centre Ltd, Tartu, Estonia, University Paris Diderot, Paris, France, University of New South Wales, Kogarah, Australia,